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Introduction Atrial fibrillation (AF) is widely recognised as a
significant cardiovascular condition associated with poor out-
comes. There is increasing evidence that abnormalities of the
cardiac autonomic nervous system (ANS) are involved in the
pathogenesis of AF. AF and hypertension commonly co-exist
and are independently associated with impaired autonomic
function determined using heart rate variability (HRV). We
decided to investigate whether HRV is more abnormal in
patients with AF and hypertension when compared to hyper-
tension alone.
Methods In a cross-sectional comparison, we studied two
patient groups: AF and hypertension (n = 61) and hyperten-
sion control group (n = 33). Time-domain, frequency-domain
and non-linear measures of HRV were determined using eMo-
tion Faros ECG sensor. Participant’s breathing was controlled
with a metronome. Data was analysed using SPSS software.
Results Participants were matched for age, sex and body mass
index (BMI). Time-domain and non-linear indices of HRV
were higher in AF (and hypertension) group compared to
hypertensive controls (p≤0.01) (table 1). AF (p=0.003), ejec-
tion fraction (p=0.04) and heart rate (p=0.04) were inde-
pendently associated with changes seen on HRV following
adjustment for multiple variables.
Conclusions First study investigating autonomic function in
patients with permanent AF and hypertension. AF, independ-
ent of hypertension, is characterised with marked HRV and is
possibly related to vagal tone.
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Introduction Radiofrequency (RF) ablation for atrial fibrillation
(AF) has traditionally been performed under general anaesthe-
sia (GA) to improve procedure tolerance and efficacy, but this
has been compromised during the COVID-19 pandemic due
to a reduction in GA availability. A very high-power short
duration (vHPSD) energy delivery protocol may reduce RF
delivery times and hence overall procedure duration, poten-
tially obviating the need for GA when using such an
approach. However, the use of vHPSD under conscious seda-
tion has not previously been reported.
We sought to evaluate first-time AF ablation using a
vHPSD approach during the COVID-19 pandemic by compar-
ing the procedural metrics and same day discharge (SDD)
rates of vHPSD against cryoballoon ablation.
Methods Procedural data was collected from consecutive
patients undergoing first-time AF ablation at two UK centres
from September 2020 to February 2021 using either the
QDot Micro catheter (Biosense Webster) or the Arctic Front
Advance Pro cryoballoon (Medtronic). In the QDot group,
vHPSD ablation (90W, 4 second lesions) was mandated for
pulmonary vein isolation (PVI), while Ablation-Index guided
50W ablation was allowed for additional lesions. Procedures
were performed under mild conscious sedation with opiates
and benzodiazepines, with a default strategy of SDD in the
absence of clinical concerns or adverse events.
Results 78 patients were evaluated, with 39 patients under-
going vHPSD and 39 receiving cryoablation. The procedural
metrics of both groups are shown in the table 1. 34 out of
39 (87%) vHPSD procedures were under conscious sedation,
and the 5 GA cases were all from the initial 2 months of
experience with the Qdot catheter. The duration of RF
energy delivery to achieve PVI using vHPSD was significantly
shorter than the equivalent duration of cryothermy. Overall
fluoroscopy times were shorter using vHPSD, while proce-
dure duration was longer. There was failure to achieve isola-
tion of all pulmonary veins in 3 (7.7%) cryoablation patients
versus none when using vHPSD ablation. In the vHPSD
group. 3 patients received adjunctive ablation beyond PVI: 1
had roof and floor lines; 1 cavotricuspid isthmus line, and 1
received a mitral isthmus line. No adjunctive ablation was
performed in the cryoablation group. SDD rates were similar
in in both groups.
Conclusion A vHPSD approach can be used with conscious
sedation to achieve same-day discharge rates for AF ablation
that are comparable to cryoablation. There are advantages
in fluoroscopy time and the required duration of ablation
delivery, as well as the versatility to handle variations in
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BMI (kg/m2) 32.9 ± 5.2 32.1 ± 4.2 0.58
HRV
Measurements
Mean [95% CI] / Median
[95% CI]
Mean [95% CI] / Median
[95% CI]
p
Heart rate 66 [61 – 72]a 60 [56 – 66]a 0.12
SDNN (ms) 62 [48 – 80]a 33 [27 – 41]a <0.001
rMSSD (ms) 97 [35 – 105]b 26 [20 – 37]b 0.002
pNN50 (%) 58 [25 – 64]b 5 [1 – 17]b <0.001
LF normalised (%) 42 [33 – 52]a* 48 [38 – 58]a 0.39
HF normalised (%) 58 [48 – 67]a* 52 [42 – 62]a 0.39
LF-i/HF-i 0.7 [0.5 – 1.1]a* 0.8 [0.6 – 1.2]a 0.61
SD1 (ms) 65 [38 – 74]b 18 [14 – 26]b <0.001
SD2 (ms) 90 [72 – 108]a 47 [36 – 58]a <0.001
SD1/SD2 0.7 [0.6 – 0.7]a 0.5 [0.4 – 0.5]a 0.002
Normally distributed data are expressed as mean ± standard deviation for descriptive data
and mean [95%confidence interval (CI)] otherwise. Identified bysuperscript a. Non-normally
distributed data are displayed as median withinterquartile ranges for descriptive data and
median [95% CI] otherwise.Identified by superscript b. Normality test was performed using
Shapiro-Wilktest. Statistical differences were tested usingindependent t-test (for parametric
data) or Mann-Whitney U test (fornon-parametric data). Significance p  0.05.
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